Clinical Trials · NCT05153590

A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland

Phase
N/A
Recruitment status
Completed
Sponsor
Novo Nordisk A/S
Enrollment
269
Start date
Dec 2021
Locations
1 site, Denmark
Primary endpoint
Relative change in body weight greater than or equal to 5% (lower BMI with weight related comorbidities) or greater than or equal to 7% (higher BMI) in reimbursed setting (yes/no)
View Liraglutide compound reference